CureVac’s mRNA Covid vaccine fails clinical trials

German drugmaker CureVac has revealed disappointing results from its mRNA trials Covid-19 VaccineInhibition hopes that pricking will help meet the global need for effective vaccination.

CureVac said on Wednesday that the vaccine dose was 47 percent effective in protecting against coronavirus in an interim analysis of its delayed trials, making it one of the least effective coronavirus vaccines tested to date.

Earlier this week, US drugmaker Novavax said the protein-based vaccine was 90% effective In the fight against coronavirus while Moderna punches and BioNTech/Pfizer are 95 percent effective in treating the original strain of the virus.

Shares of Nasdaq-listed CureVac fell 50 percent in after-market trading in New York.

The company attributed the disappointing results to new strains of the virus that were circulating in 10 countries across Latin America and Europe where its experiments were conducted.

In her study of 40,000 people, curvac He said 13 types were found in volunteers, and more than half of coronavirus cases were caused by variables of concern.

However, Data from the United Kingdom This week it showed that BioNTech/Pfizer’s competitor mRNA vaccine, or messenger ribonucleic acid, was 96 percent effective in preventing hospitalization for those with the delta variant, which was first discovered in India.

The US Centers for Disease Control and Prevention this week added the delta strain to its list of variables of concern.

CureVac has partnered with German manufacturing conglomerate Bayer to produce its own coronavirus vaccine, and has also entered into an agreement with British drugmaker GlaxoSmithKline to create a new generation of vaccines.

Poor trial results cast doubt on the viability of these projects. CureVac aims to produce 300 million doses of its vaccine this year and one billion doses in 2022.

“While we had hoped for a stronger interim result, we recognize that demonstrating high efficacy in this unprecedentedly wide variety of variants is a challenge,” said Franz Werner Haas, CEO of CureVac. The large number of variables, he added, “underscore the importance of developing next-generation vaccines.”

The vaccine is currently being studied in the UK as part of a booster trial that involves giving different shots to people who have already received two doses of the Oxford/AstraZeneca or BioNTech/Pfizer vaccines.

Like the Moderna and BioNTech/Pfizer vaccines, CureVac uses an injection of mRNA but its mRNA is natural and unmodified. The shot also uses a lower dose, 12 mcg compared to Moderna 100mg and 30mg BioNTech/Pfizer, resulting in a lower production cost, which is consistent at conventional refrigerator temperatures.

CureVac said it will continue trials of the two-dose mRNA vaccine and will decide the most appropriate regulatory path after evaluating the final trial data.

Corona virus business update

How is the coronavirus affecting markets, businesses, our daily lives and workplaces? Stay informed with our Coronavirus newsletter. Register here

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button